These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31179753)

  • 1. Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.
    Ahmadi-Zeidabadi M; Akbarnejad Z; Esmaeeli M; Masoumi-Ardakani Y; Mohammadipoor-Ghasemabad L; Eskandary H
    Electromagn Biol Med; 2019; 38(3):198-209. PubMed ID: 31179753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
    Akbarnejad Z; Eskandary H; Dini L; Vergallo C; Nematollahi-Mahani SN; Farsinejad A; Abadi MFS; Ahmadi M
    Biomed Pharmacother; 2017 Aug; 92():254-264. PubMed ID: 28551545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity of carboplatin on human glioblastoma cells is reduced by the concomitant exposure to an extremely low-frequency electromagnetic field (50 Hz, 70 G).
    Amiri M; Basiri M; Eskandary H; Akbarnejad Z; Esmaeeli M; Masoumi-Ardakani Y; Ahmadi-Zeidabadi M
    Electromagn Biol Med; 2018; 37(3):138-145. PubMed ID: 29846098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to Low-Frequency Radiation Changes the Expression of Nestin, VEGF, BCRP and Apoptosis Markers During Glioma Treatment Strategy: An
    Amirinejad M; Eftekhar-Vaghefi SH; Nematollahi Mahani SN; Salari M; Yahyapour R; Ahmadi-Zeidabadi M
    Curr Radiopharm; 2024; 17(1):55-67. PubMed ID: 38817005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of extremely low-frequency pulsed electromagnetic fields (ELF-PEMFs) on glioblastoma cells (U87).
    Akbarnejad Z; Eskandary H; Vergallo C; Nematollahi-Mahani SN; Dini L; Darvishzadeh-Mahani F; Ahmadi M
    Electromagn Biol Med; 2017; 36(3):238-247. PubMed ID: 27874284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
    Yahyapour R; Khoei S; Kordestani Z; Larizadeh MH; Jomehzadeh A; Amirinejad M; Ahmadi-Zeidabadi M
    Curr Radiopharm; 2023; 16(2):123-132. PubMed ID: 36503396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
    Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
    Liang H; Chen Z; Sun L
    Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
    Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
    Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets.
    Chien CH; Chuang JY; Yang ST; Yang WB; Chen PY; Hsu TI; Huang CY; Lo WL; Yang KY; Liu MS; Chu JM; Chung PH; Liu JJ; Chou SW; Chen SH; Chang KY
    J Biomed Sci; 2019 Oct; 26(1):77. PubMed ID: 31629402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
    Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
    Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
    Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
    Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.